M4 Receptor Antagonist Compounds With Subtype-Selective Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current muscarinic acetylcholine receptor (mAChR) antagonists for treating Parkinson's disease have dose-limiting adverse effects due to non-selectivity across mAChR subtypes, limiting their clinical efficacy and causing peripheral adverse effects and cognitive disturbances.
Innovation Solution
Development of compounds that selectively antagonize the M4 subtype of mAChR, potentially reducing adverse effects and enhancing therapeutic efficacy in treating Parkinson's disease and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective mAChR antagonists are used to treat Parkinson's disease, then motor symptoms are improved, but peripheral adverse effects and cognitive disturbances occur due to blockade of non-M4 subtypes
Solution Approach 1:
The patent applies segmentation by dividing the non-selective mAChR antagonist activity into selective M4 subtype antagonism. The compound selectively targets the M4 receptor subtype while sparing other mAChR subtypes (M1, M2, M3, M5), thereby segmenting the pharmacological effect to achieve therapeutic benefits without off-target adverse effects. This is evidenced by the compound's selective binding profile showing high affinity for M4 receptors compared to other subtypes.
Solution Approach 2:
The patent applies local quality by confining the antagonistic effect specifically to the M4 receptor subtype located in the basal ganglia circuitry. The compound exhibits localized pharmacological action at the M4 receptor site, producing antiparkinsonian effects through M4-specific pathways while avoiding systemic adverse effects associated with broader mAChR subtype blockade. The selective M4 antagonism is achieved through specific molecular interactions at the M4 receptor binding site.
2Reliability
If doses of non-selective mAChR antagonists are increased to achieve more complete blockade, then antiparkinsonian efficacy is improved, but adverse effects worsen and become dose-limiting
Solution Approach 1:
The patent resolves this contradiction by segmenting the receptor subtype selectivity to M4, allowing for effective blockade of the therapeutic target without requiring high doses that would inevitably block other subtypes. The selective M4 antagonism achieves sufficient therapeutic effect at lower doses, avoiding the dose-limiting adverse effects that plague non-selective antagonists. Clinical data shows improved motor function at tolerable dose levels.
Solution Approach 2:
The patent applies parameter changes by modifying the selectivity parameter of the antagonist compound. Instead of using non-selective antagonists with broad mAChR subtype blockade, the invention employs a compound with altered selectivity parameters that preferentially bind to M4 receptors. This parameter change in receptor subtype selectivity enables effective therapy at lower doses without the adverse effects that limit dosing of non-selective agents.
3Object-affected harmful factors
If selective M4 antagonists are developed, then adverse effects are reduced, but compound specificity and synthesis complexity increase
Solution Approach 1:
The patent applies segmentation by designing a compound with modular structure that achieves M4 selectivity through specific structural features. The molecule incorporates distinct pharmacophoric elements that confer M4 subtype preference, segmenting the molecular design to target specifically M4 receptors. This segmented approach to molecular design achieves selectivity without excessive structural complexity, maintaining synthetic feasibility.
Solution Approach 2:
The patent applies local quality by introducing specific local structural features into the compound that confer M4 selectivity. Rather than requiring complex global molecular architecture, the invention incorporates localized functional groups or structural motifs that specifically interact with M4 receptor binding sites. This localized structural modification achieves subtype selectivity with minimal increase in overall compound complexity.
Data Source
AI summary
Disclosed herein are substituted hexahydro-lH-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.